首页> 外文期刊>Current hypertension reports. >Retinal arterial hypertrophy: The new LVH?
【24h】

Retinal arterial hypertrophy: The new LVH?

机译:视网膜动脉肥大:新的LVH?

获取原文
获取原文并翻译 | 示例
           

摘要

Prevention of target organ damage represents the El Dorado for clinicians who treat hypertension. Although many of the cardiovascular sequelae of chronic hypertension are due to large artery atherosclerosis, an equal number are due to small artery dysfunction. These microvascular complications include eye disease (retinopathy), kidney failure, diastolic dysfunction of the heart and small vessel brain disease leading to stroke syndromes, dementia and even depression. Examination of the retinal vasculature represents the only way to reliably derive information regarding small arteries responsible for these diverse pathologies. This review aims to summarise the rapidly accruing evidence indicating that easily observable abnormalities of retinal arteries reflect target organ damage elsewhere in the body of hypertensive patients. In tandem, we also present putative mechanisms by which hypertension and diabetes fundamentally change small artery structure and function and how these processes may lead to target organ damage.
机译:预防靶器官损伤代表了治疗高血压的临床医生的El Dorado。尽管许多慢性高血压的心血管后遗症是由于大动脉粥样硬化引起的,但相同数量的原因是由于小动脉功能障碍。这些微血管并发症包括眼部疾病(视网膜病变),肾功能衰竭,心脏舒张功能障碍以及导致中风综合征,痴呆甚至抑郁症的小血管脑疾病。视网膜脉管系统检查是可靠地获得有关负责这些不同病理的小动脉信息的唯一方法。这篇综述旨在总结迅速累积的证据,这些证据表明易于观察到的视网膜动脉反射反映了高血压患者体内其他部位的靶器官损伤。同时,我们还提出了高血压和糖尿病从根本上改变小动脉结构和功能的推测机制,以及这些过程如何导致靶器官损伤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号